Free accessResearch articleFirst published online 2007-11
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.
Marx N., Sukhova G., Murphy C., Libby P., Plutzky J.Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol1998; 153: 17—23.
2.
Raji A., Seely EW, Bekins SA, Williams GH, Simonson DCRosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care2003; 26: 172—78.
3.
Wang TD, Chen WJ, Lin JW, Chen MF, Lee YTEffects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol2004; 93: 362—65.
4.
Yosefy C., Magen E., Kiselevich A. et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol2004; 44: 215—22.
5.
Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care2005; 28: 1547—54.
6.
Campia U., Matuskey LA, Panza JAPeroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation2006 ; 113: 867—75.
7.
Esposito K., Ciotola M., Carleo D. et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care2006; 29: 1071—76.
8.
Langenfeld MR , Forst T., Hohberg C. et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation2005; 111: 2525—31.
9.
Nakamura T., Matsuda T., Kawagoe Y. et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism2004; 53: 1382—86.
10.
Pfutzner A. , Marx N., Lubben G. et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol2005; 45: 1925—31.
11.
Pistrosch F. , Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P.In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care2004; 27: 484—90.
12.
Choi D., Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care2004; 27: 2654—60.
13.
Marx N., Wohrle J., Nusser T. et al. Pioglitazone reduces neointima volume after coronary stent implantation. A randomized, placebo-controlled, double-blind trial in nondiabetic patients . Circulation2005; 112: 2792—98.
14.
Nishio K., Sakurai M., Kusuyama T. et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care2006; 29: 101—06.
15.
Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MIEffect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation2002; 106: 679—84.
16.
Samaha FF, Szapary PO, Iqbal N. et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol2006; 26: 624—30.
17.
Satoh N., Ogawa Y., Usui T. et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care2003; 26: 2493—99.
18.
Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol2006; 26: 182—88.
19.
Marfella R. , D'Amico M., Di FC et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol2006; 47: 2444—55.
20.
Meisner F., Walcher D., Gizard F. et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol2006; 26: 845—50.
21.
Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet2005; 366: 1279—89.
22.
Hetzel J., Balletshofer B., Rittig K. et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory bio-markers. Arterioscler Thromb Vasc Biol2005; 25: 1804—809.
23.
McMahon GT, Plutzky J., Daher E., Bhattacharyya T., Grunberger G., DiCarli MFEffect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care2005; 28: 1145—50.
24.
Sidhu JS, Cowan D., Kaski JCEffects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol2004; 94: 151—56.
25.
Adachi T., Inoue M., Hara H., Maehata E., Suzuki S.Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol2004; 181: 413—17.
26.
Matthews DR , Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RCHomeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412—19.
27.
Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJEffects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism2006; 55: 907—11.
28.
Kelly AS, Kaiser DR, Dengel DR, Bank AJComparison of B-mode and echo tracking methods of assessing flow-mediated dilation. Ultrasound Med Biol2004; 30: 1447—49.
29.
Kaiser DR, Billups K., Mason C., Wetterling R., Lundberg JL, Bank AJImpaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease . J Am Coll Cardiol2004; 43: 179—84.
30.
Vallance P. , Leone A., Calver A., Collier J., Moncada S.Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol1992; 20(suppl 12): S60—S62.
31.
Stuhlinger MC, Abbasi F., Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA2002; 287: 1420—26.
32.
Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YTRelation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome . Am J Cardiol2006; 98: 1057—62.
33.
Asagami T., Abbasi F., Stuelinger M. et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism2002; 51: 843—46.
34.
Morrow JDQuantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol2005; 25: 279—86.
35.
Schwedhelm E., Bartling A., Lenzen H. et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case—control study. Circulation2004; 109: 843—48.
36.
Ceriello A.Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol2006; 17: 510—18.
37.
Home PD, Pocock SJ, Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med2007; 357: 28—38.
38.
Nissen SE, Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med2007; 356: 2457—71.
